Evidence map›Paper›PMID 28735813›Full record

ReviewCellular immunology2017

Atypical memory B cells in human chronic infectious diseases: An interim report.

Silvia Portugal, Nyamekye Obeng-Adjei, Susan Moir, Peter D Crompton, Susan K Pierce

Open access · greenAbstract readReview
In one paragraph

Review in Cellular immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 200 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. A tonsil organoid model reveals Epstein-Barr virus-infected germinal center B cell states during primary infection.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. The multilayered identity of B cell memory.Cellular & molecular immunology · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. P75iScience · 2025
    Article
  20. FcRL1, a New B-Cell-Activating Co-Receptor.International journal of molecular sciences · 2025
    Review

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Silvia PortugalCenter for Infectious Diseases, Parasitology, Heidelberg University Hospital, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.
Nyamekye Obeng-AdjeiLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Susan MoirLaboratory of Immune Regulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Peter D CromptonLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Susan K PierceLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA. Electronic address: spierce@nih.gov.
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USUniversity Hospital Heidelberg · DE

Funding

Mechanisms of naturally-acquired immunity to malaria and clinical trials of anti-malaria monoclonal antibodiesZIAAI001155 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CROMPTON, PETER · 2011 to 2025
$30.9M
Mali International Center for Excellence in Research: Malaria immunologyZIAAI001064 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERCE, SUSAN · 2009 to 2025
$25.1M
Role of B Lymphocytes In HIV Infection And PathogenesisZIAAI000825 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2009 to 2025
$24.5M
Intracellular Trafficking and Signaling Of The B-cell Antigen ReceptorZIAAI000899 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERCE, SUSAN · 2009 to 2018
$5.5M
Intracellular Trafficking Of The B-cell Antigen ReceptorZ01AI000899 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI PIERCE, SUSAN · 2001 to 2008
$625k
Intramural NIH HHS Z01 AI000899
6 · The paper itself

Abstract

Immunological memory is a remarkable phenomenon in which survival of an initial infection by a pathogen leads to life-long protection from disease upon subsequent exposure to that same pathogen. For many infectious diseases, long-lived protective humoral immunity is induced after only a single infection in a process that depends on the generation of memory B cells (MBCs) and long-lived plasma cells. However, over the past decade it has become increasingly evident that many chronic human infectious diseases to which immunity is not readily established, including HIV-AIDS, malaria and TB, are associated with fundamental alterations in the composition and functionality of MBC compartments. A common feature of these diseases appears to be a large expansion of what have been termed exhausted B cells, tissue-like memory B cells or atypical memory B cells (aMBCs) that, for simplicity's sake, we refer to here as aMBCs. It has been suggested that chronic immune activation and inflammation drive the expansion of aMBCs and that in some way aMBCs contribute to deficiencies in the acquisition of immunity in chronic infectious diseases. Although aMBCs are heterogeneous both within individuals and between diseases, they have several features in common including low expression of the cell surface markers that define classical MBCs in humans including CD21 and CD27 and high expression of genes not usually expressed by classical MBCs including T-bet, CD11c and a variety of inhibitory receptors, notably members of the FcRL family. Another distinguishing feature is their greatly diminished ability to be stimulated through their B cell receptors to proliferate, secrete cytokines or produce antibodies. In this review, we describe our current understanding of the phenotypic markers of aMBCs, their specificity in relation to the disease-causing pathogen, their functionality, the drivers of their expansion in chronic infections and their life span. We briefly summarize the features of aMBCs in healthy individuals and in autoimmune disease. We also comment on the possible relationship of human aMBCs and T-bet

Indexed as

Autoimmune DiseasesB-LymphocytesChronic DiseaseCommunicable DiseasesHIV InfectionsHumansImmunologic MemoryMalariaReceptors, Antigen, B-CellTuberculosisReceptors, Antigen, B-CellAtypical memory B cellsChronic infectious diseases

Identifiers

PMID28735813
PMCPMC5732066
OpenAlexW2735379097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.